Gabapentin in the treatment of severe sweating experienced by advanced cancer patients.
Nine patients with advanced cancer suffering from idiopathic severe sweating were treated with gabapentin (600-1,800 mg/day). All patients responded to the treatment; five patients experienced transient drowsiness. Gabapentin seems to be a safe and effective treatment for idiopathic sweating in advanced cancer patients. Further studies are warranted to confirm or refute these results.
Porzio
Giampiero
G
Supportive Care Task Force, Medical Oncology Department, University of L'Aquila, L'Aquila, Italy. porzio1@interfree.it
Aielli
Federica
F
Verna
Lucilla
L
Porto
Claudio
C
Aloisi
Paolo
P
Cannita
Katia
K
Ricevuto
Enrico
E
Marchetti
Paolo
P
Ficorella
Corrado
C
D000328:Adult; D000368:Aged; D000588:Amines / Q000008:administration & dosage / Q000627:therapeutic use*; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D000077206:Gabapentin; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000503:physiopathology*; D013546:Sweating / Q000187:drug effects*; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000627:therapeutic use*
D000588:Amines; D014151:Anti-Anxiety Agents; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin